Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

The Impact of Depression and/or Anxiety on PCI Patients

Conditions:   Acute Coronary Syndrome;   MAjor Depressive Disorder;   Generalized Anxiety Disorder
Intervention:   Other: antidepressive and anti-anxiety therapy
Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Shaanxi Provincial People's Hospital;   Xi'an Central Hospital;   Baoji Central Hospital;   Baoji People's Hospital;   General Hospital of Ningxia Medical University;   The People's Hospital of Ningxia;   Wuzhong People's Hospital;   The First Hospital of Lanzhou University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   the People's Hospital of Xinjiang Uygur Autonomous Region;   The First People's Hospital of Kashgar Erea;   the First Division Hospital of Xinjiang Production and Construction Corps
Not yet recruiting - verified December 2016

Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Coronary Thrombosis
Intervention:   Diagnostic Test: Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Completed - verified February 2017

The British Heart Foundation SENIOR-RITA Trial

Condition:   NSTEMI - Non-ST Segment Elevation MI
Interventions:   Procedure: Coronary Angiography;   Procedure: Coronary revascularisation;   Other: Optimal Medical Therapy
Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   British Heart Foundation;   Newcastle University
Recruiting - verified February 2017

Heart Rate Variability as a Predictor of Ischemic Heart Disease

Condition:   Acute Coronary Syndrome
Intervention:   Other: Heart rate variability
Sponsor:   University of Iowa
Completed - verified February 2017

Familial Investigations of Childhood Cancer Predisposition

Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Sponsor:   St. Jude Children's Research Hospital
Not yet recruiting - verified February 2017

A Strategy to Improve Implementation of LTVV for Patients w/ ARDS

Condition:   Acute Respiratory Distress Syndrome
Intervention:   Behavioral: Multi-component LTVV implementation strategy
Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2017

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Condition:   Kawasaki Disease
Intervention:   Drug: Canakinumab
Sponsor:   Novartis Pharmaceuticals
Withdrawn - verified February 2017

Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin

Condition:   Acute Coronary Syndrome
Interventions:   Drug: High dose Rosuvastatin;   Drug: Low dose Rosuvastatin
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment - at the Time of Coronary Angiography - Affect Management Strategy, Hospital Costs and Outcomes?

Conditions:   Chest Pain;   Stable Angina;   Acute Coronary Syndrome;   Non ST Segment Elevation Acute Coronary Syndrome
Intervention:   Device: Routine Measurement of FFR
Sponsors:   University Hospital Southampton NHS Foundation Trust;   Liverpool Heart and Chest Hospital NHS Foundation Trust
Recruiting - verified February 2017

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Condition:   Coronary Artery Disease
Sponsors:   Bassett Healthcare;   Baylor University
Recruiting - verified February 2017

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2016

Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon

Condition:   Hyperglycemia
Intervention:   Device: percutaneous coronary intervention
Sponsor:   Second University of Naples
Completed - verified February 2017

Observational Registry on Acute Coronary Syndromes in Campania

Condition:   Acute Coronary Syndrome
Sponsor:   Federico II University
Not yet recruiting - verified February 2017

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Condition:   Coronary Artery Disease
Interventions:   Procedure: PRU guided CABG;   Procedure: CABG per standard of care;   Device: VerifyNow assay;   Drug: Ticagrelor
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified February 2017

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study

Condition:   Congestive Heart Failure
Intervention:   Other: Monitoring on heart failure therapy
Sponsors:   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2017

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Colchicine in Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Intervention:   Drug: Colchicine vs Placebo
Sponsors:   VA Office of Research and Development;   New York University School of Medicine
Recruiting - verified February 2017

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Device: Orsiro;   Device: Xience
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals
Recruiting - verified February 2017

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Condition:   Cardiovascular Diseases
Interventions:   Drug: Ticagrelor;   Drug: Prasugrel;   Drug: Clopidogrel
Sponsors:   Erasmus Medical Center;   Covance
Completed - verified February 2017

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Condition:   Acute Coronary Syndrome
Interventions:   Drug: dalcetrapib;   Drug: Placebo
Sponsors:   DalCor Pharmaceuticals;   The Montreal Health Innovations Coordinating Center (MHICC);   Medpace, Inc.;   Roche Molecular Systems, Inc
Recruiting - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

Increased Adsorption Membranes During Cardiopulmonary Bypass

Conditions:   Cardiopulmonary Bypass;   Acute Kidney Injury;   Systemic Inflammatory Response Syndrome
Intervention:   Device: OXIRIS®
Sponsors:   Hospital Universitari de Bellvitge;   Germans Trias i Pujol Hospital;   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau;   Baxter Healthcare Corporation
Recruiting - verified February 2017

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified August 2016

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndrome
Interventions:   Drug: ticagrelor;   Drug: clopidogrel
Sponsors:   Seung-Jung Park;   AstraZeneca;   Roche Pharma AG;   KBM pharm
Active, not recruiting - verified February 2017

Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold

Condition:   Vulnerable Plaque
Intervention:   Device: Bioresorbable vascular scaffold
Sponsor:   Canisius-Wilhelmina Hospital
Terminated - verified February 2017

CCC Project- Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Sponsors:   Beijing Institute of Heart, Lung and Blood Vessel Diseases;   American Heart Association;   Chinese Society of Cardiology
Recruiting - verified February 2017

Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Conditions:   Acute Leukemia;   Myelodysplasia
Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified February 2017

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Condition:   Myocardial Injury
Interventions:   Drug: ticagrelor;   Drug: aspirin
Sponsors:   The Cleveland Clinic;   AstraZeneca
Terminated - verified February 2017

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Condition:   Acute Coronary Syndrome (ACS)
Intervention:   Drug: Ticagrelor
Sponsor:   IHF GmbH - Institut für Herzinfarktforschung
Completed - verified February 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients

Conditions:   Acute Lung Injury;   Respiratory Distress Syndrome, Adult
Sponsor:   Charite University, Berlin, Germany
Recruiting - verified February 2017

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

Conditions:   Hemophagocytic Lymphohistiocytosis;   Chronic Active Epstein-Barr Virus Infection;   Chronic Granulomatous Disease;   HIGM-1;   Leukocyte Adhesion Deficiency;   IPEX
Intervention:   Biological: Hematopoietic Stem Cell Transplant
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
Active, not recruiting - verified February 2017

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute
Recruiting - verified September 15, 2016

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Condition:   Acute Heart Failure
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2017

On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction

Condition:   Acute ST-elevation Myocardial Infarction
Intervention:   Drug: Antiplatelet Regimen Modification (aspirin or ticagrelor)
Sponsor:   Clinical Centre of Serbia
Recruiting - verified February 2017

Effects of Acute Systemic Inflammation on Arterial Stiffness and Microcirculation.

Condition:   Severe Sepsis
Intervention:   Other: NA : non interventional study
Sponsor:   Rennes University Hospital
Recruiting - verified October 2016

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Conditions:   Leukemia;   Lymphoma;   HIV
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan;   Drug: Busulfan and Fludarabine;   Drug: Cyclophosphamide and Total Body Irradiation
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
Active, not recruiting - verified February 2017

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Condition:   Leukemia, Myelocytic, Acute
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan;   Drug: Busulfan and Fludarabine;   Drug: Busulfan and Cyclophosphamide;   Drug: Cyclophosphamide and Total Body Irradiation
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
Terminated - verified February 2017

Study of Blood Samples From Newborns With Down Syndrome

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2017

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Condition:   Non-Malignant
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2017

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Completed - verified February 2017

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Procedure: PBSC transplantation;   Genetic: T cell DLI with sirolimus generated donor TH-2 cells;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim;   Genetic: T-Rapa cell DLI
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified February 3, 2017

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Conditions:   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Fanconi Anemia;   Previously Treated Myelodysplastic Syndromes
Interventions:   Drug: fludarabine phosphate;   Drug: cyclosporine;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: mycophenolate mofetil
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Completed - verified February 2017

Eligibility Screening for a NCI Pediatric Oncology Branch Research Study

Conditions:   Ewing Sarcoma;   Osteosarcoma;   Neuroblastoma;   Acute Lymphoblastic Leukemia;   Neurofibromatosis Type 1
Sponsor:   National Cancer Institute (NCI)
Enrolling by invitation - verified December 5, 2016